Skip to main content
padlock icon - secure page this page is secure

Publisher: Nature Publishing

Volume 17, Number 4, 2014

SOX2 expression in the developing, adult, as well as, diseased prostate
pp. 301-309(9)
Authors: Yu, X.; Cates, J. M.; Morrissey, C.; You, C.; Grabowska, M. M.; Zhang, J.; DeGraff, D. J.; Strand, D. W.; Franco, O. E.; Lin-Tsai, O.

Favourites:
ADD

Prognostic significance of YWHAZ expression in localized prostate cancer
pp. 310-314(5)
Authors: Ruenauver, K.; Menon, R.; Svensson, M. A.; Carlsson, J.; Vogel, W.; Andren, O.; Nowak, M.; Perner, S.

Favourites:
ADD

Polymorphisms at long non-coding RNAs and prostate cancer risk in an eastern Chinese population
pp. 315-319(5)
Authors: Cao, D. L.; Gu, C. Y.; Zhu, Y.; Dai, B.; Zhang, H. L.; Shi, G. H.; Shen, Y. J.; Zhu, Y. P.; Ma, C. G.; Xiao, W. J.

Favourites:
ADD

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study
pp. 320-324(5)
Authors: Klotz, L.; Drachenberg, D.; Singal, R.; Aprikian, A.; Fradet, Y.; Kebabdjian, M.; Zarenda, M.; Chin, J.

Favourites:
ADD

Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
pp. 325-331(7)
Authors: McKay, R. R.; Zukotynski, K. A.; Werner, L.; Voznesensky, O.; Wu, J. S.; Smith, S. E.; Jiang, Z.; Melnick, K.; Yuan, X.; Kantoff, P. W.

Favourites:
ADD

Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy
pp. 332-337(6)
Authors: Stewart, S. B.; Cheville, J. C.; Sebo, T. J.; Frank, I.; Boorjian, S. A.; Thompson, R. H.; Gettman, M. T.; Tollefson, M. K.; Umbriet, E. C.; Psutka, S. P.

Favourites:
ADD

Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study
pp. 338-342(5)
Authors: Morgans, A. K.; Fan, K. H.; Koyama, T.; Albertsen, P. C.; Goodman, M.; Hamilton, A. S.; Hoffman, R. M.; Stanford, J. L.; Stroup, A. M.; Penson, D. F.

Favourites:
ADD

Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer
pp. 343-347(5)
Authors: Valerio, M.; Stricker, P. D.; Ahmed, H. U.; Dickinson, L.; Ponsky, L.; Shnier, R.; Allen, C.; Emberton, M.

Favourites:
ADD

Who dies from prostate cancer?
pp. 348-352(5)
Authors: Patrikidou, A.; Loriot, Y.; Eymard, J. C.; Albiges, L.; Massard, C.; Ileana, E.; Di Palma, M.; Escudier, B.; Fizazi, K.

Favourites:
ADD

Association of variants in genes related to the immune response and obesity with BPH in CLUE II
pp. 353-358(6)
Authors: Lopez, D. S.; Peskoe, S. B.; Tsilidis, K. K.; Hoffman-Bolton, J.; Helzlsouer, K. J.; Isaacs, W. B.; Smith, M. W.; Platz, E. A.

Favourites:
ADD

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer
pp. 359-365(7)
Authors: Dorff, T. B.; Groshen, S.; Tsao-Wei, D. D.; Xiong, S.; Gross, M. E.; Vogelzang, N.; Quinn, D. I.; Pinski, J. K.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more